Nally Michael
Chief Executive Officer
Nally Michael has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 6, 2026.
On the most recent filing, Nally Michael is listed as Chief Executive Officer at Generate Biomedicines, Inc. Inside the rolling window, Nally Michael reported 1 open-market purchase totaling $240K in GENB and no open-market sales.
Companies traded
Other insiders at GENB
Insider Buying
$240K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Nally Michael made?
Nally Michael has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Nally Michael trade?
Nally Michael has filed SEC Form 4 disclosures for 1 company, including GENB.
When was Nally Michael's most recent SEC Form 4 filing?
Nally Michael's most recent SEC Form 4 filing on Tracefour is dated Mar 6, 2026.
What is Nally Michael's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Nally Michael is listed as Chief Executive Officer.
What is Nally Michael's total buy and sell value in the current window?
Inside the rolling retention window, Nally Michael bought $240K and sold $0 based on SEC Form 4 filings.
What was Nally Michael's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 20,000 GENB shares on 2026-03-04, worth $240K, per SEC Form 4 filings.